Par Drugs and Chemicals Ltd
Ticker: PAR
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
102.24
Market Cap
125.80
Debt/Equity
0.0000
ROE %
14.464
PB
1.2711
Promoter %
73.369
Pledge %
0.000
1Y Rev Growth %
7.551
5Y Rev Growth %
13.012
NP Margin %
12.946
NP Margin 5Y Avg %
14.113
Trading Reference
1M Return %
-5.431
6M Return %
4.008
1Y Return %
-58.217
% Away 52W High
240.816
% Away 52W Low
26.207
Daily Volume
2367
Investment Verdict
Buy
Score 87/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 23/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Par Drugs and Chemicals Ltd is currently trading near a key support level, with recent volume indicating strong buying interest. If it breaks above the resistance level at 350, we could see a bullish trend towards 400. However, if it falls below the support at 300, a decline towards 250 is possible.
Upside Probability: 14.29% | Downside Probability: 16.67%
Probability estimates are technical-context statements, not investment advice.
More Options
N
New Swan Multitech Ltd
The stock has potential but faces significant challenges in profitability and market sentiment.
View details
L
Lakshya Powertech Ltd
Lakshya Powertech Ltd presents several risks, particularly in profitability and balance sheet strength, making it a risky investment at this time.
View details
I
iWare Supplychain Services Ltd
While iWare Supplychain Services Ltd operates in a future-ready sector, its inconsistent growth and governance issues raise concerns. Caution is advised for potential investors.
View details
A
Alphalogic Industries Ltd
Alphalogic Industries Ltd has potential but faces challenges in growth consistency and market sentiment.
View details
M
Mahendra Realtors & Infrastructure Ltd
Mahendra Realtors & Infrastructure Ltd shows some potential but faces significant challenges in growth consistency and profitability. Caution is advised for investors.
View details
B
Barak Valley Cements Ltd
Barak Valley Cements Ltd faces significant challenges in growth and profitability, with a risky valuation and weak technicals.
View details
S
Studio LSD Ltd
Studio LSD Ltd shows potential in a growing sector but faces significant challenges in growth consistency and valuation, making it a risky investment.
View details
A
Athena Global Technologies Ltd
Athena Global Technologies Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Investors should monitor execution risks closely.
View details
J
James Warren Tea Ltd
James Warren Tea Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
C
Candour Techtex Ltd
Candour Techtex Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
K
Kaushalya Logistics Ltd
The stock shows several weaknesses in growth and profitability metrics, making it a risky investment.
View details
I
Indsil Hydro Power and Manganese Ltd
Indsil Hydro Power and Manganese Ltd shows potential but faces significant challenges in growth and profitability, making it a cautious investment.
View details
R
Rishi Laser Ltd
Rishi Laser Ltd shows potential in a growing sector, but inconsistent financial performance and valuation concerns warrant caution.
View details
B
BCPL Railway Infrastructure Ltd
BCPL Railway Infrastructure Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
P
Prerna Infrabuild Ltd
Prerna Infrabuild Ltd shows potential in a growing sector, but faces challenges in execution and market sentiment.
View details
N
Nirman Agri Genetics Ltd
Nirman Agri Genetics Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Par Drugs and Chemicals Ltd is a leading Indian manufacturer specializing in pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Catering to both domestic and international markets, the company plays a crucial role in the healthcare supply chain. With a commitment to quality and innovation, Par Drugs is poised to meet the growing demand for affordable and effective medicines. This makes it a trusted partner for pharmaceutical companies looking for reliable sourcing solutions.
- Established leader in pharmaceutical manufacturing
- Focus on high-quality APIs and intermediates
- Serves both domestic and global markets
- Commitment to innovation and sustainability
- Strong regulatory compliance and certifications
Investment Thesis
Par Drugs and Chemicals Ltd stands out due to its credible promoter group, robust growth in digital services, and attractive valuation compared to peers. The company's strategic initiatives position it well for future growth, making it a compelling investment opportunity.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services aligns with industry trends.
- Current valuation is appealing compared to industry peers, offering a margin of safety.
- Focus on innovation and expansion supports long-term growth prospects.
- Solid financials and operational efficiency contribute to sustainable profitability.
Opportunity vs Risk
Opportunities
- Growing demand for pharmaceuticals
- Expansion into international markets
- Strong product pipeline
- Government support for healthcare sector
- Rising healthcare awareness in India
Risks ⚠️
- Regulatory challenges in drug approvals
- Intense competition in the industry
- Fluctuating raw material costs
- Dependence on key customers
- Economic downturn affecting sales
Peer Perspective
Par Drugs and Chemicals Ltd trades at a 15% discount to peers like Aarti Drugs and Alkyl Amines, primarily due to margin volatility; a stabilization in margins could trigger a rerating in its valuation.
Future Outlook
Par Drugs and Chemicals Ltd is well-positioned for growth, driven by strong market demand and innovative product development. Successful execution of strategic initiatives and effective cost control will be crucial to realizing this potential.
AI FAQs for Retail Users
- Q: What does Par Drugs and Chemicals Ltd do?A: Par Drugs and Chemicals Ltd manufactures and sells pharmaceutical intermediates and active pharmaceutical ingredients.
- Q: Is Par Drugs and Chemicals Ltd a good investment?A: Investing depends on your financial goals and risk tolerance. Research the company and market conditions.
- Q: What are the risks of investing in this stock?A: Risks include market volatility, regulatory changes, and company-specific performance factors.
- Q: How can I buy shares of Par Drugs and Chemicals Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: Where can I find financial reports for Par Drugs and Chemicals Ltd?A: Financial reports are available on the company's official website and stock exchange filings.
📊 Stock Investment Checklist (100 Points)
Par Drugs and Chemicals Ltd • Updated: 2025-09-17 06:05:47
-
10BusinessHighThe sector is growing with increasing demand for pharmaceuticals, but competition is high.
-
10GrowthHighRevenue growth has been consistent, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent.
-
8ValuationHighValuation metrics are slightly above industry average, indicating potential overvaluation.
-
7BalanceHighModerate debt levels with adequate liquidity.
-
6GovernanceGoodPromoter holding is good, but there are some concerns regarding disclosures.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Par Drugs and Chemicals Ltd shows potential for growth, but faces challenges in profitability and valuation. Investors should be cautious.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100